shutterstock_1147238582_testing
Testing / Shutterstock.com
22 June 2020AmericasSarah Morgan

Roche accuses competitor of infringing diabetes patent

Roche Diabetes Care, a subsidiary of Switzerland-based  Roche, has accused medical device company  Insulet of infringing a patent covering a blood glucose level monitor.

In a suit filed Wednesday, June 17, Roche claimed that Insulet was infringing US patent number  7,931,613, through the sale of its Omnipod insulin management system.

The Omnipod system is made up of two parts: the pod, which delivers insulin to your body, and the personal diabetes manager, which allows you to control the pod.

Roche provides glucose monitoring, insulin delivery systems, and digital solutions for diabetes management under its brands RocheDiabetes, Accu-Chek, and mySugr.

“Insulet knew of and/or was willfully blind to the ‘613 patent and Insulet’s infringement was knowing and willful. Insulet and Roche are and were sophisticated parties and competitors in the diabetes management market and, on information and belief, Insulet identified, monitored, investigated, and assessed its competitors’ patents, including the ‘613 patent,” said the suit.

According to Roche, Insulet has publicly stated that it was aware of patents and applications owned by competitors that covered insulin infusion and related devices.

Insulet has also reportedly publicly acknowledged that third parties may have had patents on which Insulet’s products infringed, and expected to be increasingly subject to third-party infringement claims.

Roche is seeking a finding of willful infringement and triple damages.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.


More on this story

Americas
6 August 2020   The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.
Asia-Pacific
15 June 2020   Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.
Big Pharma
12 October 2023   Insulet has been awarded a preliminary injunction against EOFlow on its insulin patch pump products | Dispute and injunction come ahead of Medtronic’s planned $738m acquisition of EOFlow.

More on this story

Americas
6 August 2020   The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.
Asia-Pacific
15 June 2020   Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.
Big Pharma
12 October 2023   Insulet has been awarded a preliminary injunction against EOFlow on its insulin patch pump products | Dispute and injunction come ahead of Medtronic’s planned $738m acquisition of EOFlow.